KANEKA PHARMA AMERICA, LLC

Lobbying client · California · filed 2025 to 2025

Distributor of life science systems

$140,000 Reported spend

4 Filings counted

1 Outside firm hired

2 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page comes from one LDA client record (128509), filed by the registrant listed below.

Who filed for this client 1

KING & SPALDING LLP $140,000 Outside firm · 4 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 2

H.R. 8999
Dialysis-Related Amyloidosis Treatment Act of 2024

2 filings
H.R. 4055
Dialysis-Related Amyloidosis Treatment Act of 2025

2 filings

Reported by year 1 year

2025 $140,000 4 filings

Issues lobbied 1

Medicare/Medicaid 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 4
Centers For Medicare and Medicaid Services (CMS) 3

Recent filings 4 total

Q4 termination

KING & SPALDING LLP

4th Quarter 2025 (Oct 1 - Dec 31) · House · $40,000 income · posted Jan 19, 2026

View → Q3 report

KING & SPALDING LLP

3rd Quarter 2025 (July 1 - Sep 30) · House · $30,000 income · posted Oct 19, 2025

View → Q2 report

KING & SPALDING LLP

2nd Quarter 2025 (Apr 1 - June 30) · House · $30,000 income · posted Jul 21, 2025

View → Q1 report

KING & SPALDING LLP

1st Quarter 2025 (Jan 1 - Mar 31) · House · $40,000 income · posted Apr 17, 2025

View →

Keep going

Filings through January 19, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.